Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for chronic migraine in a US tertiary headache center

被引：0
|
作者：
Cohen, Fred [1 ]
Yuan, Hsiangkuo [1 ]
Dent, Kathryn [1 ]
Beucherie, Matthew [1 ]
Connolly, William [1 ]
Driessen, Maurice [2 ]
Krasenbaum, Lynda J. [3 ]
Carr, Karen [4 ]
Hopkins, Mary [1 ]
Marmura, Michael [1 ]
机构：
[1] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA USA
[2] Teva Netherlands BV, Global Med Affairs, Amsterdam, Netherlands
[3] Teva Branded Pharmaceut Prod R&D Inc, Global Med Affiars, W Chester, PA USA
[4] US Med Affairs, Teva Pharmaceut, Parsippany, NJ USA
来源：
CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS22-LBA
引用
收藏
页码：127 / 128
页数：2
相关论文
共 50 条
  • [41] Two year outcome of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
    Khan, Rafiullah
    Nasergivehchi, Somayeh
    Khalil, Modar
    Delroasario, Helen
    Ahmed, Fayyaz
    CEPHALALGIA, 2023, 43 (1supp) : 269 - 270
  • [42] Real-World Utilization and Safety of OnabotulinumtoxinA for Chronic Migraine Headache Prophylaxis: Interim Analysis from an Observational Study in the European Union
    Matharu, Manjit
    Pascual, Julio
    Remahl, Ingela Nilsson
    Straube, Andreas
    Johannes, Catherine
    Odom, Dawn
    Cutierrez, Lia
    Andrews, Elizabeth
    Lum, Arlene
    NEUROLOGY, 2016, 86
  • [43] First insights in real-world effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry
    Peikert, Andreas
    Koerwer, Monika
    Tozzi, Viola
    Dikow, Heidi
    Rossnagel, Fabian
    Schnabel, Silvio
    Braune, Stefan
    Bergmann, Arnfin
    NEUROLOGY, 2020, 94 (15)
  • [44] Real-world effectiveness of erenumab in Japanese patients with migraine
    Suzuki, Keisuke
    Suzuki, Shiho
    Shiina, Tomohiko
    Haruyama, Yasuo
    Kobayashi, Saro
    Shioda, Mukuto
    Hirata, Koichi
    HELIYON, 2024, 10 (04)
  • [45] Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
    Blumenfeld, Andrew M.
    Mechtler, Laszlo
    Cook, Lisa
    Rhyne, Christopher
    Jenkins, Brian
    Hughes, Olivia
    Dabruzzo, Brett
    Manack Adams, Aubrey
    Diamond, Merle
    PAIN AND THERAPY, 2024, 13 (06) : 1571 - 1587
  • [46] Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients
    Marcella Curone
    Vincenzo Tullo
    Henri Albert Didier
    Gennaro Bussone
    Neurological Sciences, 2022, 43 : 5759 - 5761
  • [47] Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients
    Curone, Marcella
    Tullo, Vincenzo
    Didier, Henri Albert
    Bussone, Gennaro
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5759 - 5761
  • [48] Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data
    Lanteri-Minet, Michel
    Ducros, Anne
    Francois, Clement
    Olewinska, Elzbieta
    Nikodem, Mateusz
    Dupont-Benjamin, Laure
    CEPHALALGIA, 2022, 42 (14) : 1543 - 1564
  • [49] Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
    Driessen, Maurice T.
    Cohen, Joshua M.
    Patterson-Lomba, Oscar
    Thompson, Stephen F.
    Seminerio, Michael
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [50] Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
    Suzuki, Shiho
    Suzuki, Keisuke
    Shiina, Tomohiko
    Haruyama, Yasuo
    Hirata, Koichi
    FRONTIERS IN NEUROLOGY, 2023, 14
12345